JPS59501712A - 「そう」痒症を治療する方法およびそのための組成物 - Google Patents
「そう」痒症を治療する方法およびそのための組成物Info
- Publication number
- JPS59501712A JPS59501712A JP57502942A JP50294282A JPS59501712A JP S59501712 A JPS59501712 A JP S59501712A JP 57502942 A JP57502942 A JP 57502942A JP 50294282 A JP50294282 A JP 50294282A JP S59501712 A JPS59501712 A JP S59501712A
- Authority
- JP
- Japan
- Prior art keywords
- naloxone
- pharmaceutically acceptable
- acceptable salt
- naltrexone
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000003251 Pruritus Diseases 0.000 title claims description 22
- 238000000034 method Methods 0.000 title claims description 14
- 239000000203 mixture Substances 0.000 title claims description 8
- RGPDIGOSVORSAK-STHHAXOLSA-N naloxone hydrochloride Chemical compound Cl.O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C RGPDIGOSVORSAK-STHHAXOLSA-N 0.000 claims description 20
- 230000007803 itching Effects 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 15
- 229960004127 naloxone Drugs 0.000 claims description 13
- 239000006071 cream Substances 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 229960005250 naloxone hydrochloride Drugs 0.000 claims description 7
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims description 6
- 229960003086 naltrexone Drugs 0.000 claims description 6
- 239000002674 ointment Substances 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 description 6
- 241000233866 Fungi Species 0.000 description 4
- 229940125715 antihistaminic agent Drugs 0.000 description 4
- 206010003399 Arthropod bite Diseases 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 230000003533 narcotic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010013647 Drowning Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000008306 shake lotion Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940025703 topical product Drugs 0.000 description 1
- 230000002568 urticarial effect Effects 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
Landscapes
- Health & Medical Sciences (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1982/001152 WO1984000889A1 (en) | 1982-08-25 | 1982-08-25 | Method of treating pruritis and composition therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS59501712A true JPS59501712A (ja) | 1984-10-11 |
Family
ID=22168155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57502942A Pending JPS59501712A (ja) | 1982-08-25 | 1982-08-25 | 「そう」痒症を治療する方法およびそのための組成物 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0116538A4 (da) |
| JP (1) | JPS59501712A (da) |
| AU (1) | AU8952282A (da) |
| DK (1) | DK206584A (da) |
| WO (1) | WO1984000889A1 (da) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009534334A (ja) * | 2006-04-21 | 2009-09-24 | ディーエスエム アイピー アセッツ ビー．ブイ． | オピオイド受容体拮抗薬の使用 |
| JP4882744B2 (ja) * | 2004-03-30 | 2012-02-22 | 東レ株式会社 | 止痒剤 |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU201675B (en) * | 1983-08-26 | 1990-12-28 | Ivan Balkanyi | Process for producing oral pharmaceutical compositions with unappetizing effect |
| US4626539A (en) * | 1984-08-10 | 1986-12-02 | E. I. Dupont De Nemours And Company | Trandermal delivery of opioids |
| US5096715A (en) * | 1989-11-20 | 1992-03-17 | Alko Ltd. | Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist |
| GB9725114D0 (en) * | 1997-11-28 | 1998-01-28 | Pfizer Ltd | Treatment of pruritus |
| US20090093509A1 (en) * | 2007-10-08 | 2009-04-09 | Tahir Nazir | Methods and Compositions for the Treatment of Pruritus |
| US20140179727A1 (en) | 2012-12-14 | 2014-06-26 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
| US8637538B1 (en) | 2012-12-14 | 2014-01-28 | Trevi Therapeutics, Inc. | Methods for treatment of pruritis |
| US8987289B2 (en) | 2012-12-14 | 2015-03-24 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
| MX2021000908A (es) | 2018-07-23 | 2021-06-08 | Trevi Therapeutics Inc | Tratamiento de la tos cronica, la dificultad respiratoria y la disnea. |
| MX2022008554A (es) | 2020-01-10 | 2022-08-10 | Trevi Therapeutics Inc | Metodos de administracion de nalbufina. |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773955A (en) * | 1970-08-03 | 1973-11-20 | Bristol Myers Co | Analgetic compositions |
| US4181726A (en) * | 1978-11-16 | 1980-01-01 | Bernstein Joel E | Method of alleviating pruritis |
-
1982
- 1982-08-25 EP EP19820902866 patent/EP0116538A4/en not_active Withdrawn
- 1982-08-25 AU AU89522/82A patent/AU8952282A/en not_active Abandoned
- 1982-08-25 JP JP57502942A patent/JPS59501712A/ja active Pending
- 1982-08-25 WO PCT/US1982/001152 patent/WO1984000889A1/en not_active Ceased
-
1984
- 1984-04-25 DK DK206584A patent/DK206584A/da not_active Application Discontinuation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4882744B2 (ja) * | 2004-03-30 | 2012-02-22 | 東レ株式会社 | 止痒剤 |
| JP2009534334A (ja) * | 2006-04-21 | 2009-09-24 | ディーエスエム アイピー アセッツ ビー．ブイ． | オピオイド受容体拮抗薬の使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU8952282A (en) | 1984-03-29 |
| EP0116538A1 (en) | 1984-08-29 |
| EP0116538A4 (en) | 1985-04-25 |
| DK206584D0 (da) | 1984-04-25 |
| DK206584A (da) | 1984-04-25 |
| WO1984000889A1 (en) | 1984-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2728284B2 (ja) | 痔疾並びにその他の治療用組成物 | |
| US6433003B1 (en) | Method for treating hyperhidrosis in mammals | |
| US6524623B1 (en) | Therapeutic compositions and methods of use thereof | |
| Hay et al. | Tioconazole nail solution—an open study of its efficacy in onychomycosis | |
| US5866143A (en) | Topical application of opioid drugs such as morphine for relief of itching and skin disease | |
| EP2481747A1 (en) | Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists | |
| JP2002536321A (ja) | 製薬組成物 | |
| DE3023588C2 (de) | Verwendung von Clonidin oder dessen Hydrochlorid zusammen mit Phentermin zum Abgewöhnen des Rauchens | |
| JPS59501712A (ja) | 「そう」痒症を治療する方法およびそのための組成物 | |
| JPH05504546A (ja) | 痛みのある疾患又はアレルギー性疾患の治療用組成物及び治療法 | |
| US4209505A (en) | Pilocarpine mouthwash for dry mouth relief | |
| JPH01501627A (ja) | 乾癬治療用組成物 | |
| US20120114743A1 (en) | Transdermal ricinoleic acid compositions | |
| Gupta et al. | Intermittent short duration therapy with fluconazole is effective for tinea capitis | |
| Schutz et al. | Local anaesthetic properties of ambroxol hydrochloride lozenges in view of sore throat | |
| US4395420A (en) | Method and composition for treating pruritis | |
| Diehl | Topical antifungal agents: An update. | |
| BLAIR et al. | Treatment of seasonal allergic rhinitis with 2% sodium cromoglycate (BP) solution | |
| JPH01246221A (ja) | フエノール含有鎮咳液体組成物 | |
| US5331012A (en) | Topical pharmaceutical preparation for fever blisters and other viral infections and method of use | |
| EP1318801B1 (en) | Topical analgesic compositions containing aliphatic polyamines and methods of using same | |
| JPH05194219A (ja) | 局所用抗かび剤 | |
| Tigerstedt et al. | Comparison of the analgesic dose‐effect relationships of nefopam and oxycodone in postoperative pain | |
| JP2008531640A (ja) | セルタコナゾール及びヒドロコルチゾン及び／又は抗菌キノロン化合物を含む抗真菌組成物 | |
| Jacobs | Treatment of fungal skin infections: state of the art |